Literature DB >> 36053473

Implementation of screening criteria for inflammatory bowel disease in patients with spondyloarthritis and its association with disease and endoscopic activity.

Jaiber Gutiérrez-Sánchez1,2, Viviana Parra-Izquierdo3,4, Cristian Flórez-Sarmiento3,4, Diego Alejandro Jaimes5, Juliette De Ávila3, Juan Manuel Bello-Gualtero1,2, Alejandro Ramos-Casallas3, Lorena Chila-Moreno2,3, César Pacheco-Tena6, Adriana Beltrán-Ostos3, Philippe Chalem-Choueka7, Wilson Bautista-Molano2,3, Consuelo Romero-Sánchez8,9,10.   

Abstract

There is little literature on the implementation of screening criteria for inflammatory bowel disease (IBD) in patients with spondyloarthritis (SpA). This study aimed to apply IBD screening criteria in a group of patients with SpA without IBD diagnosis and correlate them to endoscopic findings and disease activity. A total of 82 patients with SpA were included. The IBD screening test and ileocolonoscopy with digital chromoendoscopy with magnification and histological analysis were performed. The data were analysed with Chi-square test/Fisher's exact test and multiple correspondence analysis. The major screening criteria found in 48.7% of the patients were associated with a history of infection (p = 0.037). Rectal bleeding was associated with the diagnosis of ankylosing spondylitis, acute inflammation, enthesitis and tissue architecture alteration in the ileum (p < 0.050). Diarrhoea was associated with a higher disease activity score (p = 0.02). Minor screening criteria were associated with painful inflammatory joint (p = 0.05), high disease activity score (p = 0.001) and high calprotectin levels (p = 0.050). Abdominal pain (36.9%) was associated with axial/peripheral compromise (p = 0.017), inflammatory back pain (p = 0.01), enthesitis (p = 0.021), higher disease activity score (p = 0.023) and acute ileum inflammation (p = 0.046). Diarrhoea of 4 weeks and abdominal pain were the most prevalent major and minor screening criteria, respectively, being related to early manifestations of inflammatory bowel compromise and higher disease activity score. This screening test grants a chance of opportune referral of SpA patients from rheumatology to gastroenterology.
© 2022. The Author(s).

Entities:  

Keywords:  Calprotectin; Ileocolonoscopy; Inflammatory bowel disease; Spondyloarthritis

Year:  2022        PMID: 36053473     DOI: 10.1007/s10067-022-06297-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  16 in total

1.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

Review 2.  Biochemical aspects of infection in rheumatoid arthritis and ankylosing spondylitis.

Authors:  V Neumann
Journal:  Baillieres Clin Rheumatol       Date:  1988-04

Review 3.  Ankylosing spondylitis: how should the disease be assessed?

Authors:  Maxime Dougados; Désirée van der Heijde
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-09       Impact factor: 4.098

4.  Survival rate in Crohn's disease and ulcerative colitis.

Authors:  L Storgaard; N Bischoff; F W Henriksen; K Fischerman; S Jarnum
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

Review 5.  Ankylosing spondylitis and bowel disease.

Authors:  Martin Rudwaleit; Dominique Baeten
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-06       Impact factor: 4.098

6.  Acute effects of smoking during modified sham feeding in duodenal ulcer patients. An analysis of nicotine, acid secretion, gastrin, catecholamines, epidermal growth factor, prostaglandin E2, and bile acids.

Authors:  G Lindell; L O Farnebo; D Chen; E Nexø; J Rask Madsen; K Bukhave; H Graffner
Journal:  Scand J Gastroenterol       Date:  1993-06       Impact factor: 2.423

Review 7.  Ankylosing spondylitis: an autoimmune or autoinflammatory disease?

Authors:  Daniele Mauro; Ranjeny Thomas; Giuliana Guggino; Rik Lories; Matthew A Brown; Francesco Ciccia
Journal:  Nat Rev Rheumatol       Date:  2021-06-10       Impact factor: 20.543

8.  Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model.

Authors:  Liesbet Van Praet; Filip E Van den Bosch; Peggy Jacques; Philippe Carron; Lennart Jans; Roos Colman; Elien Glorieus; Harald Peeters; Herman Mielants; Martine De Vos; Claude Cuvelier; Dirk Elewaut
Journal:  Ann Rheum Dis       Date:  2012-11-08       Impact factor: 19.103

Review 9.  Update on spondyloarthropathies.

Authors:  Muhammad Asim Khan
Journal:  Ann Intern Med       Date:  2002-06-18       Impact factor: 25.391

10.  Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis.

Authors:  H Cypers; G Varkas; S Beeckman; K Debusschere; T Vogl; J Roth; M B Drennan; M Lavric; D Foell; C A Cuvelier; M De Vos; J Delanghe; F Van den Bosch; D Elewaut
Journal:  Ann Rheum Dis       Date:  2015-12-23       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.